Search results for "Numa"

showing 10 items of 74 documents

Migranti: lager bipartisan

2014

detenzione amministrativa centri di identificazione ed espulsione politiche migratorie forme di confinamento e trattamenti inumani e degradantiSettore SPS/08 - Sociologia Dei Processi Culturali E Comunicativi
researchProduct

Il c.d. 41-bis è una forma di tortura o trattamento crudele, inumano o degradante?

2009

L'articolo analizza i profili di incompatibilità del regime penitenziario c.d. 41 bis con la normativa e la giurisprudenza internazionale in materia di trattamenti inumani o degradanti

detenzione 41 bis ordinamento penitenziario diritti fondamentali tortura trattamento inumano o degradanteSettore IUS/17 - Diritto Penale
researchProduct

Scalp psoriasis: report of efficient treatment with secukinumab

2018

Background: Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the population in the world. The scalp is the most common, and frequently the first site of disease involvement. Occasionally it may be the only localization of psoriasis. Objective: Treatment of scalp psoriasis is often unsatisfactory, due to limited available topical therapy and reduced efficacy of some systemic drugs. Biologic therapies are recommended for severe psoriasis, resistant to topical treatment, but evidence from randomized, controlled studies is lacking regarding effectiveness on scalp-localized lesions. The aim of this paper is to show our experience on the efficacy of secukinumab on scalp psoriasi…

education.field_of_studymedicine.medical_specialtyintegumentary systembusiness.industryPopulationDermatologyDiseaseControlled studiesmedicine.diseaseDermatologybody regions030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesisScalpPsoriasismedicineEffective treatmentSecukinumabeducationbusinessScalp psoriasisScalp psoriasisJournal of Dermatological Treatment
researchProduct

La fides e la promessa: forme di reciprocità tra dèi e uomini nella riscrittura di Ovidio

2017

Nelle rielaborazioni ovidiane dei racconti mitici greci, emergono diversi casi in cui la relazione tra esseri umani e divinità è riscritta alla luce della nozione romana di fides. Ma se la quasi totalità di questi miti, in cui il dio promette all’interagente mortale un pegno, un dono o un privilegio, è giustificata dalla presenza di vincoli di tipo amoroso, parentale o devozionale, un caso a parte rappresenta il racconto di Numa Pompilio e Giove (Fast. 3. 285-392) – un racconto Romano – in cui l’agente umano merita i pignora certa del dio e instaura con lui un rapporto di reciprocità. Il contributo si propone di esaminare questa rappresentazione della fides pollicita attraverso un confronto…

fides promise Fasti Metamorphoses Ovid pledge Numa Midas reciprocity gift Anius' daughterfides promessa Fasti Metamorfosi Ovidio pegno Numa Mida reciprocità dono le figlie di Anio.Settore L-FIL-LET/04 - Lingua E Letteratura Latina
researchProduct

Reduced CD27−IgD− B Cells in Blood and Raised CD27−IgD− B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel Disease

2019

The intestinal mucosa in inflammatory bowel disease (IBD) contains increased frequencies of lymphocytes and a disproportionate increase in plasma cells secreting immunoglobulin (Ig)G relative to other isotypes compared to healthy controls. Despite consistent evidence of B lineage cells in the mucosa in IBD, little is known of B cell recruitment to the gut in IBD. Here we analyzed B cells in blood of patients with Crohn's disease (CD) and ulcerative colitis (UC) with a range of disease activities. We analyzed the frequencies of known B cell subsets in blood and observed a consistent reduction in the proportion of CD27−IgD− B cells expressing all Ig isotypes in the blood in IBD (independent o…

mass cytometrylcsh:Immunologic diseases. Allergyimmune system diseasesinflammatory bowel diseasememory B cellsGALThemic and immune systemschemical and pharmacologic phenomenabiologicslcsh:RC581-607digestive system diseasesustekinumabFrontiers in Immunology
researchProduct

SAT0511 CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: CLINICAL INACTIVE DISEASE RATE AND SAFETY IN ITALIAN PATIENTS

2019

Background: Systemic juvenile idiopathic arthritis (sJIA) is a polygenic autoinflammatory disease. The innate immune mechanisms play a central role with overproduction of inflammatory cytokines. The increased knowledge on the role of these cytokines has provided a change in the natural history of the disease with the introduction of the targeted treatments. Remarkable results has been observed with canakinumab, an anti-interleukin-1β monoclonal antibody, in two clinical trials but little information are available in real life. Objectives: To evaluate clinical inactive disease rate and safety of canakinumab in Italian patients with sJIA. Methods: We have collected retrospectively clinical an…

medicine.medical_specialtyAnakinraeducation.field_of_studybusiness.industryPopulationmedicine.diseaseRashEtanerceptchemistry.chemical_compoundCanakinumabTocilizumabchemistryMacrophage activation syndromeInternal medicineInjection site reactionMedicinemedicine.symptombusinesseducationmedicine.drugSaturday, 15 June 2019
researchProduct

P215 Blood-based prognostic biomarkers in Crohn’s patients treated with biologics: a new promising tool to predict endoscopic outcomes

2021

Abstract Background There is a growing need for biomarkers of inflammation to monitor and predict therapeutic outcome in Crohn’s disease (CD) patients. We aimed to evaluate whether the level of circulating blood cells, expressed as ratios (NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ELR, eosinophil-to-lymphocyte ratio and ENLR, eosinophil*neutrophil-to-lymphocyte ratio), could be used as early prognostic biomarker of endoscopic response (ER) in patients starting biological therapy with infliximab, adalimumab, vedolizumab and ustekinumab. Association with steroid-free clinical remission at week 54 and endoscopic disease activity at baseline, as well as other varia…

medicine.medical_specialtyCrohn's diseasePredictive markermedicine.diagnostic_testbusiness.industryGastroenterologyInflammationGeneral Medicinemedicine.diseaseGastroenterologyInfliximabVedolizumabEndoscopyInternal medicineUstekinumabmedicineAdalimumabmedicine.symptombusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Review of biologics in allergic contact dermatitis

2020

The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes its management challenging. With advances in the understanding of the cellular and molecular pathogenesis of ACD, newer therapeutic targets are becoming apparent. In particular, the use of biologics has gained momentum, given the specificity of their action. This article aims to review the presently available data on the use of biologics in ACD. English-language-based literature available on the use of biological therapy was thoroughly probed in the following databases as on October 14, 2019: PubMed, Google Scholar, The Cochrane library, Embase, Scopus, and EBSCO. The following keywords were used: "conta…

medicine.medical_specialtyDermatologyOmalizumabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineUstekinumabmedicineAdalimumabHumansImmunology and Allergy030212 general & internal medicineAllergic contact dermatitisBiological Productsbusiness.industryPatch Testsmedicine.diseaseDermatologyDupilumabInfliximabTreatment OutcomeDermatitis Allergic ContactSecukinumabbusinessmedicine.drugContact Dermatitis
researchProduct

The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1.

2021

medicine.medical_specialtyDrug Industrybusiness.industryGeneral NeuroscienceMEDLINEGeneral MedicineDiseaseAntibodies Monoclonal HumanizedRaising (linguistics)United StatesPsychiatry and Mental healthClinical PsychologyAlzheimer DiseaseMedicineHumansAducanumabGeriatrics and GerontologybusinessIntensive care medicineDrug ApprovalJournal of Alzheimer's disease : JAD
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct